Eli Lilly will buy AurKa Pharma in a deal potentially worth up to $575 million, the U.S. drugmaker said on Monday, seeking access to the privately held firm’s experimental cancer treatment for solid tumors.
The deal is Lilly’s second in less than a week that aims to broaden its portfolio of lucrative cancer drugs. On Thursday, Lilly said it would buy Armo BioSciences for about $1.6 billion.
AurKa Pharma will receive $110 million upfront and is eligible to earn up to $465 million more if it achieves regulatory and sales milestones.
AurKa’s chief drug under development was discovered by Lilly, but the drugmaker sold the compound in 2016 to TVM Capital Life Science, which established AurKa.
The drug, AK-01, is being studied in early-stage trials to treat multiple types of solid tumors.